Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Intraocular Lymphoma × Procarbazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 17 Hodgkin Disease 10 Central Nervous System Neoplasms 4 Recurrence 3 Lymphoma, Non-Hodgkin 3 Glioblastoma 3 Astrocytoma 3 Oligodendroglioma 2 Neurotoxicity Syndromes 2 Lymphoma, Follicular 2 Lymphoma, AIDS-Related 2 Radiation Injuries 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Intraocular Lymphoma 1 Gliosarcoma 1 Glioma 1 Burkitt Lymphoma 1 Brain Neoplasms 1

Interventions

Rituximab 7 Methotrexate 6 Cyclophosphamide 6 Peripheral Blood Stem Cell Transplantation 5 fludarabine phosphate 4 Dexamethasone 4 Cytarabine 4 Cyclosporine 4 Whole-Body Irradiation 3 Tacrolimus 3 Radiotherapy 3 Mycophenolic Acid 3 Filgrastim 3 pegfilgrastim 2 etoposide phosphate 2 Lenalidomide 2 Granulocyte Colony-Stimulating Factor 2 Etoposide 2 Busulfan 2 Antilymphocyte Serum 2 zanubrutinib 1 sodium thiosulfate 1 sargramostim 1 oblimersen 1 merphos 1 ibrutinib 1 Vorinostat 1 Transplantation 1 Thiotepa 1 Therapeutics 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00074191 2017-04-21

Protocol-A

OHSU Knight Cancer Institute

Phase 2 Completed

Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡